Abstract: The present invention discloses novel proinsulin glargine and method for for preparing insulin glargine therefrom. A sequence of the proinsulin glargine containing SOD fusion peptide subjected to site-directed mutagenesis and “0 C peptide” is designed; recombinant Escherichia coli for expressing insulin glargine are constructed; insulin glargine fusion protein in a form of an inclusion body is expressed; and denaturation, renaturation, modification, enzyme digestion, separation and purification are carried out to obtain a mature insulin glargine active pharmaceutical ingredient. According to the present invention, the SOD fusion peptide sequence is mutated to enhance the fermentation yield of the insulin glargine by 75%; and a “0 C peptide” strategy is adopted to reduce the quality loss and miscleavage impurities in the enzyme digestion transformation. The purity of the insulin glargine active pharmaceutical ingredient prepared in the present invention is up to 99.

Abstract: Provided a bolt-bearing circumferential device for reinforcing and correcting an angle iron of a transmission tower, comprising a reinforcing angle iron, a holding hoop, and a connector; the reinforcing angle iron is arranged at an inner side of two limbs of an angle iron to be reinforced, an axis direction of the reinforcing angle iron is parallel to the angle iron to be reinforced, and an outer wall of two limbs of the reinforcing angle iron are fitted with an inner wall of the angle iron to be reinforced; the holding hoop is arranged at an outer side of the reinforcing angle iron and the angle iron to be reinforced, and each part of the holding hoop are connected together through the high-strength bolts; a side wall of the holding hoop is provided with three groups of threaded holes, wherein an axis of a first group of the threaded holes and an axis of a second group of the threaded holes are perpendicular to each other, a first group of bolts pass through the first group of the threaded holes to apply a r

Abstract: A patterned substrate includes a substrate body having a surface and a plurality of patterned structures periodically arranged on the surface of the substrate body, where each of the patterned structures includes a first portion formed on the surface of the substrate body, and a second portion formed on the first portion, and where any two adjacent ones of the patterned structures are spaced apart from one another by a minimum distance of not greater than 0.1 ?m. A light-emitting diode includes the patterned substrate and a semiconductor epitaxial structure formed thereon. A process for preparing the patterned substrate and a process for preparing the light-emitting diode are also disclosed.

Abstract: A power supply system is applied to the electronic device, where the electronic device includes at least two cell groups, an external interface, and a load; the power supply system includes a toggle switch circuit and a buck switch circuit; two poles of the cell group are respectively coupled to an input end of the toggle switch circuit; a first output end of the toggle switch circuit is coupled to an input end of the buck switch circuit, a second output end of the toggle switch circuit is coupled to an output end of the buck switch circuit, and the input end of the buck switch circuit is coupled to an external interface; and the output end of the buck switch circuit is further coupled to the load, and the external interface is configured to connect a charger.

Abstract: A performance analysis system includes a picker module and a calculation circuit. The picker module is placed in the processing device to capture a plurality of pieces of time information of a unit circuit of each of a plurality of tasks in the processing device during total execution time of processing the plurality of tasks. The calculation circuit performs an interval analysis operation on the time information. The interval analysis operation includes: calculating an overlap period between a current task and a previous task; and counting time occupied by the unit circuit during the total execution time of processing the tasks by the processing device according to a relation between the current time interval of the current task corresponding to the unit circuit and the overlap period.

Abstract: The present disclosure provides a touch panel and a positioning method thereof. The touch panel includes: a transparent conductive film layer including a plurality of first self-capacitance touch electrodes arranged along a first direction, wherein the plurality of first self-capacitance touch electrodes are configured to detect a coordinate of a touch point in the first direction, at least one of the plurality of first self-capacitance touch electrodes is a transparent conductive film block extending along a second direction, and the first direction intersects with the second direction; and a wire layer including a plurality of second self-capacitance touch electrodes arranged along the second direction, wherein the plurality of second self-capacitance touch electrodes are configured to detect a coordinate of the touch point in the second direction, and at least one of the plurality of second self-capacitance touch electrodes is a group of wires extending along the first direction.

Abstract: Provided herein are solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Vadadustat, Code: AKB-6548, Compound 1), compositions comprising such solid forms, and methods of making and using thereof.

Abstract: The present disclosure provides a multi-screen video display method, a video display device, a computer apparatus, and a medium. The video display method includes: selecting in response to a first operation and a second operation of a user, a start point and an end point in a multi-screen control icon of a graphical user interface, and showing a sub-layout according to the start point and the end point, wherein the multi-screen control icon comprises multiple sub-icons, the sub-icons are objects respectively mapping sub-screens in the multi-screen display to the graphical user interface, and the sub-layout comprises all covered sub-icons from the start point to the end point; determining the sub-layout in response to a third operation of the user; and generating a video display template in response to a fourth operation of the user, and showing a video display on the graphical user interface.

Abstract: Provided are crystalline forms of N-(5{5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide fumaric acid, in particular Form A and a N-(5{5-((1R,2S)-2-fluorocyclo-propyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide fumaric acid co-crystal. Provided are also the processes for preparation of such crystalline forms. Furthermore, Provided is a pharmaceutical composition comprising said N-(5{5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide fumaric acid Form A, or said N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide fumaric acid co-crystal, and at least one pharmaceutically acceptable excipient.

Abstract: Provided are methods involving the assaying of a labeled cell suspension, e.g., to detect cancer-related cells, populations ON thereof and/or screen for metastatic cancer. Labeled cell suspensions may be assayed to detect whether a tumor infiltrating lymphocyte (TIL) population is present in a cellular suspension of a subject. Cancer-related cell populations of interest include, e.g., those expressing one or more markers, including where the markers are members of a marker panel. Markers assayed may vary depending on the context and may include protein markers, nucleic acid markers, cell cycle markers, DNA content markers, and the like. Useful markers include one or more immune checkpoint markers and/or one or more immune cell-type markers, including where the marker(s) assayed are part of one or more panels of markers. Also provided are methods of treating a subject for a neoplasia based on the outcome of an assay of a labeled cell suspension of sample from a subject.

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

Abstract: The present disclosure provides a method, apparatus and system for guiding diagnosis-and-treatment, and a computer readable storage medium. The method for guiding diagnosis-and-treatment includes the following steps: acquiring basic process information of the diagnosis-and-treatment; determining flow progress information; and generating a diagnosis-and-treatment flowchart and corresponding status indication information according to the basic flow information and the flow progress information, wherein the status indication information indicates a status progress of at least one flow-stage in the diagnosis-and-treatment flowchart.

Abstract: Provided herein are solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Vadadustat, Code: AKB-6548, Compound 1), compositions comprising such solid forms, and methods of making and using thereof.

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

Abstract: The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Abstract: A fast startup power oscillator transmitter includes a transistor pair that drives a resonant circuit including a tunable capacitance. A capacitor array preferably forms the tunable capacitance. A voltage booster activates the capacitor array. A clamped body bias voltage booster can set the body bias voltage of the transistor pair in one circuit. Control circuitry activates the resonant circuit through a triode-mode switch transistor in response to an input in a range of 0.3-0.6V, and preferably while controlling the substrate bias voltage of the transistor pair to increase transconductance of the cross-coupled transistor pair. In a variation, a circuit pushes a top plate voltage of one of the two capacitors to 2VDD and pulls the top plate voltage of the other to zero to give the oscillator an initial condition.

Abstract: A hollow-core antiresonant fiber (HC-ARF) with nested supporting rings (NSRs) has a fiber structure that includes from the inside out a fiber core, a first silica antiresonant ring (SARR), a first air antiresonant ring (AARR), a second SARR, a second AARR and an external silica wall. The fiber structure further includes a first NSR within the first AARR and a second NSR within the second AARR. The HC-ARF with NSRs has advantages and benefits of low confined loss (CL), large bandwidth, simple structure and very good bending characteristics. Therefore, the application fields of HC-ARF are greatly expanded.

Abstract: A fast startup power oscillator transmitter includes a transistor pair that drives a resonant circuit including a tunable capacitance. A capacitor array preferably forms the tunable capacitance. A voltage booster activates the capacitor array. A clamped body bias voltage booster can set the body bias voltage of the transistor pair in one circuit. Control circuitry activates the resonant circuit through a triode-mode switch transistor in response to an input in a range of 0.3-0.6V, and preferably while controlling the substrate bias voltage of the transistor pair to increase transconductance of the cross-coupled transistor pair. In a variation, a circuit pushes a top plate voltage of one of the two capacitors to 2 VDD and pulls the top plate voltage of the other to zero to give the oscillator an initial condition.